Skip to main content
Erschienen in: Infection 6/2014

01.12.2014 | Clinical and Epidemiological Study

Diagnostic performance of serum high-sensitivity procalcitonin and serum C-reactive protein tests for detecting bacterial infection in febrile neutropenia

verfasst von: Mizuki Aimoto, Hideo Koh, Takako Katayama, Hiroshi Okamura, Takuro Yoshimura, Shiro Koh, Satoru Nanno, Mitsutaka Nishimoto, Asao Hirose, Mika Nakamae, Takahiko Nakane, Hirohisa Nakamae, Hiroshi Kakeya, Masayuki Hino

Erschienen in: Infection | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Although a few prospective studies have addressed the question as to which biomarker of infection in adult patients with febrile neutropenia (FN) is superior, procalcitonin (PCT) or C-reactive protein (CRP), the results have been inconsistent and inconclusive. This was possibly due to the poor sensitivity of previous PCT tests that have a functional sensitivity of 0.5 ng/ml.

Methods

Between November 2010 and February 2012, we prospectively compared the diagnostic utility of serum high-sensitivity (hs) PCT (lower limit of detection, 0.02 ng/ml) and CRP levels for detecting bacterial infection in patients with FN. Serum was collected within 72 h after the onset of FN in patients with hematological disorders.

Results

Seventy-five febrile episodes were evaluable. The areas under the receiver operating characteristic curves for life-threatening infection defined as septic shock and bacteremia caused by non-coagulase negative staphylococcus were 0.824 (95 % CI 0.711–0.937; P = 0.001) for hsPCT and 0.673 (0.505–0.842; P = 0.068) for CRP, respectively. In contrast, CRP, but not hsPCT, tended to increase significantly with the clinical severity, as indicated by the diagnostic classification (P = 0.002 for trend).

Conclusions

The serum hsPCT test may be more useful than the serum CRP test in the detection of life-threatening infection at an early phase after the onset of FN. In contrast, the serum CRP test may be more useful in diagnosing the severity of infection. However, neither of these tests was able to differentiate the cause of FN with a low probability of fatal outcome.
Literatur
1.
Zurück zum Zitat Klastersky J, Ameye L, Maertens J, Georgala A, Muanza F, Aoun M, Ferrant A, Rapoport B, Rolston K, Paesmans M. Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents. 2007;30(Suppl 1):S51–9.PubMedCrossRef Klastersky J, Ameye L, Maertens J, Georgala A, Muanza F, Aoun M, Ferrant A, Rapoport B, Rolston K, Paesmans M. Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents. 2007;30(Suppl 1):S51–9.PubMedCrossRef
2.
Zurück zum Zitat Manian FA. A prospective study of daily measurement of C-reactive protein in serum of adults with neutropenia. Clin Infect Dis. 1995;21:114–21.PubMedCrossRef Manian FA. A prospective study of daily measurement of C-reactive protein in serum of adults with neutropenia. Clin Infect Dis. 1995;21:114–21.PubMedCrossRef
3.
Zurück zum Zitat Jimeno A, García-Velasco A, del Val O, González-Billalabeitia E, Hernando S, Hernández R, Sánchez-Muñoz A, López-Martín A, Durán I, Robles L, Cortés-Funes H, Paz-Ares L. Assessment of procalcitonin as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia. Cancer. 2004;100:2462–9.PubMedCrossRef Jimeno A, García-Velasco A, del Val O, González-Billalabeitia E, Hernando S, Hernández R, Sánchez-Muñoz A, López-Martín A, Durán I, Robles L, Cortés-Funes H, Paz-Ares L. Assessment of procalcitonin as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia. Cancer. 2004;100:2462–9.PubMedCrossRef
4.
Zurück zum Zitat Schüttrumpf S, Binder L, Hagemann T, Berkovic D, Trümper L, Binder C. Procalcitonin: a useful discriminator between febrile conditions of different origin in hemato-oncological patients? Ann Hematol. 2003;82:98–103.PubMed Schüttrumpf S, Binder L, Hagemann T, Berkovic D, Trümper L, Binder C. Procalcitonin: a useful discriminator between febrile conditions of different origin in hemato-oncological patients? Ann Hematol. 2003;82:98–103.PubMed
5.
Zurück zum Zitat Giamarellou H, Giamarellos-Bourboulis EJ, Repoussis P, Galani L, Anagnostopoulos N, Grecka P, Lubos D, Aoun M, Athanassiou K, Bouza E, Devigili E, Krçmery V, Menichetti F, Panaretou E, Papageorgiou E, Plachouras D. Potential use of procalcitonin as a diagnostic criterion in febrile neutropenia: experience from a multicentre study. Clin Microbiol Infect. 2004;10:628–33.PubMedCrossRef Giamarellou H, Giamarellos-Bourboulis EJ, Repoussis P, Galani L, Anagnostopoulos N, Grecka P, Lubos D, Aoun M, Athanassiou K, Bouza E, Devigili E, Krçmery V, Menichetti F, Panaretou E, Papageorgiou E, Plachouras D. Potential use of procalcitonin as a diagnostic criterion in febrile neutropenia: experience from a multicentre study. Clin Microbiol Infect. 2004;10:628–33.PubMedCrossRef
6.
Zurück zum Zitat Prat C, Sancho JM, Dominguez J, Xicoy B, Gimenez M, Ferra C, Blanco S, Lacoma A, Ribera JM, Ausina V. Evaluation of procalcitonin, neopterin, C-reactive protein, IL-6 and IL-8 as a diagnostic marker of infection in patients with febrile neutropenia. Leuk Lymphoma. 2008;49:1752–61.PubMedCrossRef Prat C, Sancho JM, Dominguez J, Xicoy B, Gimenez M, Ferra C, Blanco S, Lacoma A, Ribera JM, Ausina V. Evaluation of procalcitonin, neopterin, C-reactive protein, IL-6 and IL-8 as a diagnostic marker of infection in patients with febrile neutropenia. Leuk Lymphoma. 2008;49:1752–61.PubMedCrossRef
7.
Zurück zum Zitat Becker KL, Snider R, Nylen ES. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit Care Med. 2008;36:941–52.PubMedCrossRef Becker KL, Snider R, Nylen ES. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit Care Med. 2008;36:941–52.PubMedCrossRef
8.
Zurück zum Zitat Svaldi M, Hirber J, Lanthaler AI, Mayr O, Faes S, Peer E, Mitterer M. Procalcitonin-reduced sensitivity and specificity in heavily leucopenic and immunosuppressed patients. Br J Haematol. 2001;115:53–7.PubMedCrossRef Svaldi M, Hirber J, Lanthaler AI, Mayr O, Faes S, Peer E, Mitterer M. Procalcitonin-reduced sensitivity and specificity in heavily leucopenic and immunosuppressed patients. Br J Haematol. 2001;115:53–7.PubMedCrossRef
9.
Zurück zum Zitat Lin CH, Yao M, Hsu SC, Ho CC, Lin MT, Lin CA, Hu FC, Yu CJ, Tien HF. Soluble triggering receptor expressed on myeloid cells-1 as an infection marker for patients with neutropenic fever. Crit Care Med. 2011;39:993–9.PubMedCrossRef Lin CH, Yao M, Hsu SC, Ho CC, Lin MT, Lin CA, Hu FC, Yu CJ, Tien HF. Soluble triggering receptor expressed on myeloid cells-1 as an infection marker for patients with neutropenic fever. Crit Care Med. 2011;39:993–9.PubMedCrossRef
10.
Zurück zum Zitat Masaoka T. Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan: executive summary. Clin Infect Dis. 2004;39(Suppl 1):S49–52.PubMedCrossRef Masaoka T. Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan: executive summary. Clin Infect Dis. 2004;39(Suppl 1):S49–52.PubMedCrossRef
11.
Zurück zum Zitat Tamura K, Imajo K, Akiyama N, Suzuki K, Urabe A, Ohyashiki K, Tanimoto M, Masaoka T, Japan Febrile Neutropenia Study Group. Randomized trial of cefepime monotherapy or cefepime in combination with amikacin as empirical therapy for febrile neutropenia. Clin Infect Dis. 2004;39(Suppl 1):S15–24.PubMedCrossRef Tamura K, Imajo K, Akiyama N, Suzuki K, Urabe A, Ohyashiki K, Tanimoto M, Masaoka T, Japan Febrile Neutropenia Study Group. Randomized trial of cefepime monotherapy or cefepime in combination with amikacin as empirical therapy for febrile neutropenia. Clin Infect Dis. 2004;39(Suppl 1):S15–24.PubMedCrossRef
12.
Zurück zum Zitat Kagebayashi C, Yamaguchi I, Akinaga A, Kitano H, Yokoyama K, Satomura M, Kurosawa T, Watanabe M, Kawabata T, Chang W, Li C, Bousse L, Wada HG, Satomura S. Automated immunoassay system for AFP-L3% using on-chip electrokinetic reaction and separation by affinity electrophoresis. Anal Biochem. 2009;388:306–11.PubMedCrossRef Kagebayashi C, Yamaguchi I, Akinaga A, Kitano H, Yokoyama K, Satomura M, Kurosawa T, Watanabe M, Kawabata T, Chang W, Li C, Bousse L, Wada HG, Satomura S. Automated immunoassay system for AFP-L3% using on-chip electrokinetic reaction and separation by affinity electrophoresis. Anal Biochem. 2009;388:306–11.PubMedCrossRef
13.
Zurück zum Zitat From the Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel. J Infect Dis. 1990;161:397–401.CrossRef From the Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel. J Infect Dis. 1990;161:397–401.CrossRef
14.
Zurück zum Zitat American College of Chest Physicians/Society of Critical Care. Medicine consensus conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20:864–74.CrossRef American College of Chest Physicians/Society of Critical Care. Medicine consensus conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20:864–74.CrossRef
15.
Zurück zum Zitat Kanda Y. Investigation of the freely-available easy-to-use software “EZR” (Easy R) for medical statistics. Bone Marrow Transplant. 2012;48:452–8.PubMedCentralPubMedCrossRef Kanda Y. Investigation of the freely-available easy-to-use software “EZR” (Easy R) for medical statistics. Bone Marrow Transplant. 2012;48:452–8.PubMedCentralPubMedCrossRef
16.
Zurück zum Zitat Póvoa P, Souza-Dantas VC, Soares M, Salluh JF. C-reactive protein in critically ill cancer patients with sepsis: influence of neutropenia. Crit Care. 2011;15:R129.PubMedCentralPubMedCrossRef Póvoa P, Souza-Dantas VC, Soares M, Salluh JF. C-reactive protein in critically ill cancer patients with sepsis: influence of neutropenia. Crit Care. 2011;15:R129.PubMedCentralPubMedCrossRef
17.
Zurück zum Zitat Müller B, White JC, Nylén ES, Snider RH, Becker KL, Habener JF. Ubiquitous expression of the calcitonin-i gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab. 2001;86:396–404.PubMed Müller B, White JC, Nylén ES, Snider RH, Becker KL, Habener JF. Ubiquitous expression of the calcitonin-i gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab. 2001;86:396–404.PubMed
18.
Zurück zum Zitat Morgenthaler NG, Struck J, Chancerelle Y, Weglöhner W, Agay D, Bohuon C, Suarez-Domenech V, Bergmann A, Müller B. Production of procalcitonin (PCT) in non-thyroidal tissue after LPS injection. Horm Metab Res. 2003;35:290–5.PubMedCrossRef Morgenthaler NG, Struck J, Chancerelle Y, Weglöhner W, Agay D, Bohuon C, Suarez-Domenech V, Bergmann A, Müller B. Production of procalcitonin (PCT) in non-thyroidal tissue after LPS injection. Horm Metab Res. 2003;35:290–5.PubMedCrossRef
19.
Zurück zum Zitat Linscheid P, Seboek D, Schaer DJ, Zulewski H, Keller U, Müller B. Expression and secretion of procalcitonin and calcitonin gene-related peptide by adherent monocytes and by macrophage-activated adipocytes. Crit Care Med. 2004;32:1715–21.PubMedCrossRef Linscheid P, Seboek D, Schaer DJ, Zulewski H, Keller U, Müller B. Expression and secretion of procalcitonin and calcitonin gene-related peptide by adherent monocytes and by macrophage-activated adipocytes. Crit Care Med. 2004;32:1715–21.PubMedCrossRef
20.
Zurück zum Zitat Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR, Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52:e56–93.PubMedCrossRef Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR, Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52:e56–93.PubMedCrossRef
Metadaten
Titel
Diagnostic performance of serum high-sensitivity procalcitonin and serum C-reactive protein tests for detecting bacterial infection in febrile neutropenia
verfasst von
Mizuki Aimoto
Hideo Koh
Takako Katayama
Hiroshi Okamura
Takuro Yoshimura
Shiro Koh
Satoru Nanno
Mitsutaka Nishimoto
Asao Hirose
Mika Nakamae
Takahiko Nakane
Hirohisa Nakamae
Hiroshi Kakeya
Masayuki Hino
Publikationsdatum
01.12.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Infection / Ausgabe 6/2014
Print ISSN: 0300-8126
Elektronische ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-014-0657-6

Weitere Artikel der Ausgabe 6/2014

Infection 6/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.